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Abstract We assessed the safety and efﬁcacy of sorafe-
nib with cryotherapy (cryoRx) in advanced hepatocellular
carcinoma (HCC). One hundred four HCC patients were
enrolled, who met the following criteria: (i) Barcelona
Clinic Liver Cancer stage C; (ii) HCC without distant
metastasis; (iii) the presence of portal vein thrombosis
(PVT); (iv) Child-Pugh class A or B; and (v) life expec-
tancy of at least 12 weeks. The patients were randomly
divided into sorafenib-cryoRx and sorafenib (control)
groups. Primary endpoint was time to progression (TTP);
secondary endpoints included overall survival (OS) and
tolerability. Microvessel density (MVD) was assessed by
CD34-immunostaining. After a median 10.5 (4–26) months
follow-up, the data showed that median TTP was 9.5
(8.4–13.5) months in combinatorial therapy group vs. 5.3
(3.8–6.9) months in sorafenib group (P = 0.02). The
median OS was 12.5 (95 % CI 10.6–16.4) months in
combination therapy group vs. 8.6 (7.3–10.4) months in
sorafenib group (P = 0.01). Low MVD patients in com-
bination therapy exhibited signiﬁcantly longer median TTP
and OS than controls. High MVD was predictive of poor
responses to sorafenib. CryoRx did not increase frequency/
degree of sorafenib-related adverse events. Therefore, it
was concluded that the addition of cryoRx signiﬁcantly
improved clinical outcomes of Sorafenib therapy in
advanced HCC with acceptable tolerance and similar safety
proﬁles as previously reported.
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Introduction
Hepatocellular carcinoma (HCC) is the third most common
cause of cancer-related deaths worldwide [1] and the second
most common cause in China [2]. Most patients with
advanced HCC at the time of initial diagnosis exhibit poor
outcomes [3]. In China, HCC is most commonly caused by
infectionwiththehepatitisBvirus(HBV)[4].Theincidence
of HCC has increased in recent years, largely because of
chronic HBV infection-related liver cirrhosis [5]. Thera-
peutic options are stage-dependent [6, 7]. Only about 30 %
of patients who presented with early-stage tumors undergo
resection, liver transplantation, and percutaneous ablation
due to various factors, such as multifocal tumor and poor
liverfunctionresultingfromunderlyingcirrhosis[8–10].For
a long period, no effective treatment was available for these
conditions[11].Sorafenibisanewlydeveloped,molecularly
targeted agent. This multikinase inhibitor demonstrated
signiﬁcant survival beneﬁts in phase III trials for patients
with advanced HCC [12, 13]. However, its efﬁcacy remains
moderate,andsomepatients stillshow avery shortperiodof
survival following treatment [14].
The mechanisms causing some patients to become
refractory to sorafenib are currently unclear. High intratu-
moral microvessel density (MVD) was associated with
higher level of VEGF/VEGHFR signaling pathway activity.
As such, the presence of high MVD in advanced HCC
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rafenibtreatment.Itiscurrentlyunknown,however,whether
the presence of high intratumoral MVD can affect responses
to sorafenib treatment in advanced HCC patients. Several
previous ﬁndings suggest a strong rationale for combining
both treatment modalities. In mice with implanted renal
tumors, the combination of radiofrequency ablation and so-
rafenib was found to cause an increase in the efﬁcacy of
tumor ablationthat was dependent on sorafenib dosage [15].
Cryotherapy (cryoRx), based on in situ freezing and devi-
talizationoftissues,hasbeen foundmoreadvantageousthan
surgical resection in cirrhotic patients because its focal
application results in the loss of less hepatic parenchyma.
Moreover, it is possible to treat several liver segments and
the technique can be applied and controlled precisely to
produce a predictable zone of necrosis. This technology has
been used extensively in open surgical settings and, more
recently, applied percutaneously to treat renal tumors and
liver metastases [16, 17]. Therefore, the aim of the current
study was to conﬁrm the efﬁcacy and safety of combined
application of sorafenib and cryotherapy in advanced HCC,
and to also study the ablation tumor burden impact for
sorafenib therapy responses.
Materials and Methods
Patients’ Classiﬁcation and Eligibility Criteria
Based on the Barcelona Clinic Liver Cancer (BCLC)
staging classiﬁcation [7], 296 consecutive patients with
HBV-related advanced HCC were screened between July
2008 and July 2010 at the Center of Therapeutic Research
for Hepatocellular Carcinoma, Beijing the 302nd Hospital,
China. Fifty-seven patients were classiﬁed as Child-Pugh
C, 38 patients with Child-Pugh B8 or B9 and their serum
bilirubin mean level was [51.3 lmol/L. Twenty three
patients had life expectancy of \12 weeks. Ten patients
had Eastern Cooperative Oncology Group Performance
Status (ECOG PS) C3, and 64 patients with a history of
hepatectomy (8), preoperative chemotherapy (6), prior
transarterial chemoembolization (TACE) or local ablation
(44), and radiotherapy (6). As a result, 192 patients were
excluded from this study. Thus, a total of 104 patients with
advanced HCC were eligible for this study (Table 1). The
diagnosis of HCC [6] was indicated by imaging ﬁndings
and conﬁrmed by biopsy (single action biopsy device,
16 g; Promex Technologies, USA). PVT, as a sign of
macroscopic vascular invasion and extrahepatic spread,
was used to deﬁne advanced HCC, but patients exhibiting
extrahepatic spread were excluded from the study. Eligi-
bility criteria also included the ECOG PS of 0, 1, or 2;
Child-Pugh class A or B; life expectancy of at least
12 weeks; total bilirubin concentration of B51.3 lmol/L;
and HBsAg positive status. In addition, the patients con-
sidered for inclusion were required to exhibit at least one
tumor lesion that could be measured along one dimension
according to modiﬁed Response Evaluation Criteria in
Solid Tumors (mRECIST) assessment for HCC [18].
Study Design
According to Sorafenib HCC Assessment Randomized
Protocol(SHARP)trial[13],theoverallsurvival(OS)rateof
the advanced HCC patients for sorafenib at the 15th month
was 37 %. The sample size calculation was based on the
detection of signiﬁcant differences in OS, the second end-
pointparameterofthistrial,assumingthatOSratewas50 %
for the combination therapy group at the 15th month. A total
of90patientswererequiredforalog-ranktestwithanoverall
two-sided signiﬁcance level of 0.05 and power of 0.805.
From our experience, it can be expected that 15–20 % of the
patients will drop out after randomization. In order to
accommodateforthedrop-outrate,thetotalsamplesizewas,
therefore, increased to 104. The study was investigator ini-
tiated and was approved by the institutional ethics commit-
tee.Writteninformedconsentwasobtainedfromthepatients
before enrollment. All the eligible patients were randomly
assigned, with a 1:1 ratio, to either sorafenib ? cryoRx
group (N = 52) or sorafenib-alone group (N = 52) using
simple randomization by means of computer to achieve a
balance between the two groups. None of the patients had
prior treatment, such as chemotherapy or radiation therapy.
Sorafenib Administration
All the patients received sorafenib at a dose rate of 400 mg
twice daily for at least 8 weeks. Treatment interruptions and
dose reductions (ﬁrst to 400 mg twice daily, and then to
200 mg twice daily) were permitted in case of adverse drug
reactions (ADRs) according to the National Cancer Institute
Common Toxicity Criteria [19]. For ADRs of grades 3–4,
sorafenib was withdrawn to 200 mg twice daily until the
ADRs improved to grade B2, and then increased to 400 mg
twice daily if well tolerated. The discontinuation of therapy
metthefollowingcriteria:ADRsthatrequiredterminationof
medication, deterioration of ECOG PS score to 4, and
withdrawal of consent. If disease progression was observed,
then sorafenib was continued when the patient was consid-
eredtohaveagoodclinicalstatus(e.g.,PS,liverfunctionand
tolerable side effects) and wished to continue the treatment.
Following sorafenib treatment, cryoRx were conducted in
those without absolute contraindications, based on the
potential clinical beneﬁts expected from the treatment and
the patient’s consent. Sorafenib therapy was continued
without interruption during local therapies.
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Argon–helium cryoablation was performed as we described
elsewhere [20]. In brief, the size and number of probes
depended on the location and the average size of the lesions
to be ablated. An argon–helium gas-based CryoCare sys-
tem (EndoCare, Inc., CA, USA) and cryoprobes (2 and
3 mm) were used to freeze the tumor with a dual freeze–
thaw cycle under ultrasound-guidance. Based on patient’s
ECOG PS, liver function and tolerable side effects, tumor
burden, or new recurrence was best cryoablated in four
times at most.
CD34 Immunohistochemical Staining
All the samples from the HCC patients were reviewed
histologically using hematoxylin and eosin (H&E) stain-
ing; the parafﬁn-embedded samples were cut into 5-lm-
thick sections and processed for immunohistochemistry
according to the manufacturer’s instructions and as
previously described [21, 22]. Tumorous sections were
immunostained with human CD34 monoclonal antibody
(BioGenex, San Ramon, CA, USA). The tissue sections
were incubated with primary CD34 monoclonal antibody
(BioGenex, CA, USA) diluted 1:50 with Tris-buffered
saline solution for 60 min at room temperature. Afterward,
as secondary-biotinylated anti-mouse immunoglobulin
antibody (Dako, USA) was used at a concentration of
1.0 lg/mL and allowed to react for 30 min at 37 C. Then,
streptavidin-biotinylated horseradish peroxidase complex
(Dako, USA) was added. The negative control was
obtained by substituting primary antibodies with mouse
immunoglobulin G (IgG).
Determination of Microvessel Density
The intratumoral MVD was evaluated by two independent
observerswhowereblindedtothepatients’clinicaldata.The
tissue sections were screened at a low power ﬁeld (940) and
ﬁve areas with the most intense neovascularization (hot
Table 1 Demographic and
baseline characteristics of
patients
HBV Hepatitis B virus, ECOG
Eastern Cooperative Oncology
Group
Characteristic Combination therapy (N = 52) Sorafenib (N = 52)
Age (years) 51.2 ± 11.9 52.6 ± 8.3
Gender (no; %)
Male 48 (92.3) 47 (90.4)
Female 4 (7.7) 5 (9.6)
ECOG performance status (no; %)
0 16 (30.8) 17 (32.7)
1 29 (55.7) 30 (58)
2 7 (13.5) 5 (9)
BCLC stage C (no; %) 52 (100) 52 (100)
Tumor diameter (cm; range) 8.39 ± 4.38 (3.5–12.8) 8.32 ± 2.72 (3.2–13.2)
Number of tumor sites (no; %)
1 7 (13.5) 6 (11.5)
2 9 (17.3) 10 (19.2)
3 10 (19.2) 11 (21.2)
C4 26 (50) 25 (48.1)
Macroscopic vascular invasion (no; %)
Branch 36 (69.3) 37 (71.2)
Trunk 16 (30.7) 15 (28.8)
Tumor differentiation (no; %)
Well 9 (17.3) 10 (19.2)
Intermediate 30 (57.7) 30 (57.7)
Poorly 13 (25) 12 (23.1)
HBV-DNA positivity (no; %)
100–9,999 22 (42.3) 24 (46.2)
10,000–99,999 19 (36.5) 18 (34.6)
C100,000 11 (21.2) 10 (19.2)
Child-Pugh class (no; %)
A 41 (78.8) 43 (83)
B 11 (21.2) 9 (17)
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123spots) were selected. Microvessel counts of these areas were
performed under a high power ﬁeld (9200). To reduce
observer-related variation, counting of microvessels was
performed using computer image analyzer (MetaMorph
ImagingSystemVersion3.0;UniversalImagingCorp,West
Chester, PA, USA). Microvessels, tumor cells, and connec-
tive elements were counted as one microvessel, irrespective
of the presence of a vessel lumen. The mean microvessel
count of the ﬁve most vascular areas was taken to constitute
the MVD which was expressed as the absolute number of
microvessels per 0.74 mm
2 (at 9200 magniﬁcation).
Disease Assessment
The disease assessment was performed by computed tomog-
raphy (CT) scan or magnetic resonance imaging (MRI),
approximately every 8 weeks. Response was determined by
independent radiologists and classiﬁed according to mRE-
CIST assessment for HCC [18]. In this study, responses were
classiﬁedintocompleteresponse(CR),partialresponse(PR),
stabledisease(SD),orprogressivedisease(PD).Patientswho
achieved CR, PR, or SD were deﬁned as achieving clinical
beneﬁts (CB). Patients who exhibited CR or PR were deﬁned
as achieving a clinical efﬁcacy response (CER).
End Points
The primary endpoint of the study was time to progression
(TTP). The secondary endpoints included OS, the disease-
control rate (DCR), and tolerability. TTP was calculated
from the date of commencement of sorafenib to the date of
disease progression or death. OS was calculated from the
date of commencement of sorafenib to the date of death or
the last follow-up.
Statistical Analysis
The data were analyzed using SPSS13 statistical software
package (SPSS, Chicago, IL, USA) and expressed as
median and range values. All continuous data were clas-
siﬁed into subgroups according to the median for analysis.
Associations between OS, TTP, and potential prognostic
factors were assessed by the Kaplan–Meier method (log-
rank test) in a univariate analysis. All P-values\0.05 were
considered statistically signiﬁcant.
Results
Patients’ Characteristics
The combination therapy and sorafenib alone groups
were well balanced with regard to baseline demographic
and disease characteristics (Table 1). Eighty-four (80.8 %)
patients were classiﬁed as Child-Pugh class A, and 20
(19.2 %) patients were Child-Pugh class B. Thirty-three
(31.7 %) patients were ECOG PS 0, 59 (56.7 %) were
ECOG PS 1, and 12 (11.6 %) were ECOG PS 2. The tumor
differentiation was well in 19 (18.3 %) patients, interme-
diate in 60 (57.7 %), and poorly in 25 (24.0 %). The HBV
DNA loads were low in 46 (44.2 %) patients, moderate in
37 (35.6 %), and high in 21 (20.2 %).
Adverse Events
With regard to non-hematologic toxicity, rash was
observed most commonly (62 %), followed by hyperten-
sion (56 %), weight loss (52.9 %), alopecia (50 %), diar-
rhea (46 %), fatigue (43.3 %), hand-foot skin reaction
(HFSR; 42 %), liver dysfunction (34.6 %), voice change
(18 %), abdominal pain (12.5 %), and upper gastrointesti-
nal tract bleeding (16 %). Moreover, grade 3 or 4 non-
hematologic toxicities included HFSR, diarrhea, liver
dysfunction, and upper gastrointestinal tract bleeding
which occurred in 12.2, 12, 6.4, and 6 % of patients,
respectively. With respect to hematologic toxicity, leuko-
penia was the most common sign of toxicity (24 %), fol-
lowed by thrombocytopenia (12 %) and anemia (8 %). All
four patients with anemia exhibited grade 3 or 4 toxicity,
and one patient’s hemoglobin was reduced to 32 g/L.
Overall Response and Efﬁcacy
The median follow-up time was 10.5 (range 4.0–26.0)
months, and the median duration of sorafenib treatment was
7.5 (2.5–26.0) months. Ten (9.6 %) patients discontinued
sorafenib at 6–24 weeks on account of liver function dete-
rioration (6 cases) and esophagogastric varices bleeding (4
cases), 21 (20.2 %) patients received the reduced sorafenib
dosage (200 mg twice daily) because of grades 3–4 ADRs,
but all these patients restored to 400 mg twice daily dose
after 1–2 weeks. Overall, the patients receiving combina-
tion therapy had a median OS of 12.5 (95 % CI 10.6–16.4)
months, compared with 8.6 (95 % CI 7.3–10.4) months for
those receiving sorafenib alone (log-rank P = 0.009;
Fig. 1a). In addition, the patients in combination therapy
group had a signiﬁcantly longer median TTP (9.5 months;
95 % CI 8.4–13.5 months) than the patients in sorafenib
alone (5.3 months; 95 % CI 3.8–6.9 months) group (log-
rank P = 0.024; Fig. 1b). Regarding the analysis for best
response, 4 of 52 (7.6 %) patients in combination therapy
exhibitedCR,9(17.3 %)patients exhibitedPR,22(42.3 %)
patients exhibited SD, whereas in the sorafenib 4 (7.6 %)
and 19 (36.5 %) patients exhibited PR and SD, respectively.
The rates of CER and DCR (Table 2) were signiﬁcantly
higher for combination therapy (CER 22 % and DCR 66 %)
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DCR 46.2 %; P = 0.0272). Both combination therapy and
sorafenib alone exhibited a clinical beneﬁt in all preplanned
subgroup analyses, despite some patients having charac-
teristics associated with poor prognosis including poorer
ECOG PS, tumor diameter[7 cm, high HBV DNA load,
Child-Pugh class B, fatigue, weight-loss, abdominal pain,
and liver dysfunction (Table 3). Disease progression
occurred in 86 (82.6 %) patients. Furthermore, 53 (50.9 %)
patients died that included: 25 (24.0 %) due to recurrence/
metastasis, 13 (12.5 %) due to liver failure, 8 (7.7 %) due
to esophagogastric varices bleeding, 4 (3.8 %) due to
refractoryascites-inducedrenalfailure, and 3(2.9 %)dueto
tumor rupture/hemorrhage.
Response and Efﬁcacy According to Intratumoral
Microvessel Density
Intratumoral microvessels density was observed by anti-
CD34immunostaining(9200;pinkstaining;left:lowMVD-
CD34;right:highMVD-CD34;Fig. 2A).Speciﬁcstainingof
capillary-like vessels was observed in all outcome groups
(CR ? PR: mean MVD-CD34, 111 ± 49/0.74 mm
2,S D
206 ± 74/0.74 mm
2, PD 339 ± 92/0.74 mm
2; Fig. 2B).
Fig. 1 Kaplan–Meier estimates of OS and TTP. a Kaplan–Meier
survival curves are shown for 52 patients treated with combination
therapy and 52 patients treated with sorafenib alone. Median OS was
signiﬁcantly longer (P = 0.009) in patients from combination therapy
group than in patients from sorafenib alone group; b Kaplan–Meier
survival curves showing signiﬁcantly longer TTP (P = 0.04) in
patients from combination therapy group than in patients from
sorafenib alone group
Table 2 Summary of efﬁcacy measures
Outcome Combination therapy (n = 52) Sorafenib (n = 52) P-value
Over survival (months) 0.009
Median 12.5 8.6
95 % CI 10.6–16.4 7.3–10.4
TTP (months) 0.024
Median 9.5 5.3
95 % CI 8.4–13.5 3.8–6.9
Level of response (no; %)
Complete response 4 (7.6) 0 NA
Partial response 9 (17.3) 5 (9.6) 0.1186
Stable disease 22 (42.3) 19 (36.5) 0.4423
Clinical efﬁcacy rate (no; %) 13 (25.0) 5 (9.6) 0.0414
Disease control rate (no; %) 35 (67.3) 24 (46.2) 0.0272
Clinical efﬁcacy rate It was deﬁned as the proportion of patients who had the best response rating of complete response or partial response which
was maintained for C4 weeks from the ﬁrst manifestation of that rating
Disease control rate It was deﬁned as the proportion of patients who had the best response rating of either complete/partial response or stable
disease which was maintained for C4 weeks from the ﬁrst manifestation of that rating
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(CR ? PR) patients was signiﬁcantly lower than that in PD
patients (P\0.001). At the time of analysis, the prognostic
inﬂuence of MVD on the overall response and efﬁcacy was
evaluated by comparing OS or TTP between patients with
low or high tumor MVD, determined by their median MVD
Table 3 Univariate analysis of patients’ demographic and clinical characteristics for predictive factors of DCR, TTP and OS
Parameter No. of patients P-value of DCR TTP (months) OS (months)
Total DCR PD Died Median P Median P
Sex 1.000 0.514 0.781
Male 95 54 41 48 6.0 10.5
Female 9 4 5 5 4.5 9.0
Age 0.526 0.668 0.228
B51 52 28 24 28 5.0 9.0
[51 52 30 22 25 6.0 10.5
ECOG PS \0.001 \0.001 \0.001
0 33 23 10 10 8.5 17.0
1 59 31 28 35 6.0 11.0
2 12 4 8 8 3.0 6.5
Tumor differentiation 0.473 0.155 0.401
Well 19 11 8 10 4.0 8.0
Intermediate 60 34 26 29 4.5 9.0
Poorly 25 13 12 14 3.5 7.0
Tumor diameter (cm) 0.034 0.025 0.007
B7 52 38 17 19 6.5 12.0
[7 50 20 29 34 4.0 8.1
Tumor number 0.012 0.165 0.995
1 13 11 2 3 6.0 12.7
2 19 13 6 7 6.0 11.0
3 21 15 6 12 5.0 10.0
4 51 19 32 31 4.0 10.0
HBV DNA (IU/mL) 0.001 \0.001 \0.001
0–9,999 46 30 16 17 6.0 12.7
10,000–99,999 37 20 17 21 4.0 10.0
C100,000 21 8 13 15 3.0 8.0
Child-Pugh class 0.027 \0.001 0.004
A 84 51 33 39 6.0 9.5
B 20 7 13 14 3.5 5.0
Fatigue 0.002 \0.001 \0.001
Grade 0 59 39 20 21 7.0 13.0
Grades 1–4 45 19 26 32 4.0 8.1
Weight loss \0.001 0.001 \0.001
Grade 0 49 39 10 13 6.5 11.2
Grades 1–4 55 19 36 40 4.0 7.0
Abdominal pain 0.043 0.034 0.006
Grade 0 91 54 37 45 6.5 11.0
Grades 1–4 13 4 9 8 3.0 5.0
Liver dysfunction \0.001 \0.001 \0.001
Grade 0 68 44 14 29 7.0 12.1
Grades 1–4 36 14 32 24 3.0 7.5
PD progressive disease; DCR disease control rate; TTP time to progression; OS overall survival; ECOG Eastern Cooperative Oncology Group;
PS performance status; HBV hepatitis B virus
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123Fig. 2 Comparison of
intratumoral microvessels
density (MVD)-CD34 in
patients with advanced HCC
and showing different overall
responses. A Intratumoral
microvessels density shown by
anti-CD34 immunostaining
(pink staining; left low MVD-
CD34; right high MVD-CD34;
9200). B Mean intratumoral
MVD-CD34 increased
signiﬁcantly (P\0.001) with
poor overall response. C A
cohort of 104 patients was
analyzed. Kaplan–Meier
survival curves are shown for 52
patients with low MVD-CD34
(B219.5/0.74 mm
2). In this
cohort, TTP (a) and OS
(b) compared between patients
from combination therapy group
and sorafenib alone group
differed signiﬁcantly. Also,
Kaplan–Meier survival curves
are shown for 52 patients with
high MVD-CD34 ([219.5/
0.74 mm
2). In this cohort, TTP
(c) and OS (d) compared
between patients from
combination therapy group and
sorafenib alone group differed
signiﬁcantly
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2, ranging from 34 to
512/0.74 mm
2). When the entire cohort of 104 patients was
analyzed, 52 patients were found to show a lower than
median MVD-CD34 (B219.5/0.74 mm
2). TTP and OS
(Fig. 2C—a, b) differed signiﬁcantly between combination
therapy and sorafenib alone (log-rank: P = 0.018 for TTP;
P = 0.023forOS).Inthe52patientsexhibitingahigherthan
median MVD-CD34 ([219.5/0.74 mm
2), TTP and OS
(Fig. 2C—c, d; Table 4) differed non-signiﬁcantly between
combination therapy and sorafenib alone (log-rank:
P = 0.312 for TTP; P = 0.062 for OS).
Continuation of Sorafenib in a Subset of Patients
with Radiologic PD Improved OS
At the end of follow-up, disease progression occurred in 86
patients. In 36 patients, sorafenib therapy was discontinued
because of new lesions or concomitant clinical deteriora-
tion. However, 50 patients with a clinically stable presen-
tation continued sorafenib therapy, despite disease
progression. As shown in Fig. 3, OS was signiﬁcantly
longer (P\0.001) in patients who continued sorafenib
(11 months) as compared with those who discontinued
therapy (7.5 months).
Discussion
To our knowledge, this report is the ﬁrst to describe that
cryotherapy is associated with improved clinical outcomes
Table 4 Univariate analysis of advanced HCC patients’ intratumoral MVD as a predictor of DCR, time to progressive, and OS
Parameter No. of patients P-value of DCR TTP (months) OS (months)
Total DCR PD Died Median 95 % CI P Median 95 % CI P
Sorafenib ? CryoRx \0.001 0.007 0.006
MVD-CD34 low 25 23 2 7 11.0 17.5
8.5–14.5 15.2–19.8
MVD-CD34 high 27 12 15 14 6.0 9.0
5.5–6.5 7.0–12.3
Sorafenib 0.002 0.049 0.012
MVD-CD34 low 26 14 12 12 5.0 9.5
1.8–8.1 7.0–12.0
MVD-CD34 high 26 9 17 20 3.5 6
2.6–4.4 4.6–8.2
MVD-CD34 low \0.001 0.018 0.023
Sorafenib ? Cryo 25 23 2 7 11.5 17.5
8.8–14.9 15.2–19.8
Sorafenib 26 14 12 12 5 9.5
2.0–8.1 7.0–12.0
MVD-CD34 high 0.312 0.303 0.062
Sorafenib ? Cryo 27 12 15 14 5 9
4.5–6.5 6.9–11.1
Sorafenib 26 9 17 20 3.5 7
2.6–4.4 5.8–8.2
HCC hepatocellular carcinoma; MVD microvessel density; TTP time to progression; OS overall survival; DCR disease control rate; PD
progressive disease; CryoRx cryotherapy
Fig. 3 Kaplan–Meier analysis of the effect of continuing sorafenib
therapy on OS in patients with radiologic PD. OS was signiﬁcantly
longer (P\0.001) in PD patients from continuing sorafenib group
than in PD patients from discontinued therapy group
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123in combination with sorafenib treatment for advanced
HCC. Systemic chemotherapy has had a disappointing
track record for treating advanced HCC [23]. However,
sorafenib demonstrated a signiﬁcant survival beneﬁt and
high tolerance in patients with advanced HCC in a phase III
clinical trial [13]. Sorafenib was found to restrict tumor
burden limit in advanced HCC [24]. It is important to
reduce tumor burden to increase the clinical responses of
drugs. Ablation therapies have been proposed as valid
alternatives to surgery for the treatment of HCC in patients
with cirrhosis [25]. A few studies have examined the out-
comes of percutaneous cryoRx for HCC using CT moni-
toring and MR guidance, reporting that it was safe and
effective [26, 27]. Moreover, it was found that not only was
the local tumor necrotic, but the adjacent tumor tissue was
also necrotic and shrunken in HCC patients following
cryoRx, which was regarded as reﬂecting ectopic tumor
suppression [28]. We reported that after cryoablation for
small HCC the 1-, 2-, and 3-year recurrence-free survival
rates were 72, 56, and 43 %, respectively [20]. As such,
local recurrence after cryotherapy represents one of the
main problems of this therapeutic strategy, and limits its
associated survival beneﬁts.
We speculated that combined sorafenib and cryoRx
could be used to overcome tumor burdens and local
recurrence in advanced HCC patients and provide signiﬁ-
cant survival beneﬁts. Of note, in the present study, the
median OS time of combination therapy patients was
12.5 months which was signiﬁcantly longer than that of
patients receiving sorafenib alone (8.6 months). In addi-
tion, the combination therapy signiﬁcantly prolonged TTP
and CER or DCR compared with sorafenib alone. The
signiﬁcant improvements in OS and TTP in the combina-
tion therapy provide encouraging evidence that the com-
bination therapy may help overcome the tumor burden and
local tumor recurrence. Indeed, the OS we report is longer
than that reported in all previous studies on sorafenib
treatment of advanced HCC patients [12, 13, 29–31]. All
the patients in our study had advanced HCC (100 % of
BCLC stage C and of HBV DNA positive) with macro-
scopic vascular invasion. In 50 % of our patients, the
largest tumor diameter was[7 cm, and this characteristic
suggests that the patients enrolled in our study might have
more tumor burden than those enrolled in the previously
reported trial [12, 13]. In the Asia–Paciﬁc study [12], the
median OS and TTP were 6.5 months and 2.8 months,
respectively; and the population showed poorer perfor-
mance (74 % ECOG PS C1) and a more advanced stage of
cancer (96 % of BCLC stage C). In the SHARP study [13],
the median OS and TTP were 10.7 months and 4.1 months,
respectively; and the population exhibited a more advanced
stage of cancer (82 % of BCLC stage C; 38 % macroscopic
vascular invasion, and 51 % extrahepatic spread). The
12.5-month OS and 8.5-month TTP found in patients with
PVT in the combination therapy are particularly impres-
sive, in accordance with the rationale for the combination
treatments by previous ﬁndings. Although we found that
sorafenib could prolong survival in advanced HCC
patients, monotherapy of sorafenib has not been found to
produce tumor regression in HCC. Rather, high tumor load
may render patients refractory to sorafenib [24]. In accor-
dance with the above-referred evidence, our results suggest
that the combination therapy has several advantages. First,
the cryoRx can reduce the tumor burden to increase the
efﬁcacy of sorafenib. Second, sorafenib-mediated blockage
of the Raf/MAPK and VEGFR pathways may enhance the
efﬁcacy of local cryoRx. Both these possibilities are sup-
ported by the present data. The clinical beneﬁts of this
treatment may be due largely to the reduction of tumor
burden by cryoRx which corroborates the previous ﬁndings
examining the effects of local ablation combined with
TACE [32]. More importantly, addition of the cryoRx to
sorafenib could further improve OS in these HCC patients;
the proﬁle, frequency, and degree of sorafenib-related
adverse events (AEs) were comparable to previous reports
and cryoRx did not further increase frequency and degree
of sorafenib-related AEs. These encouraging results indi-
cate that sorafenib combined with local treatment may
provide the best therapeutic beneﬁt in patients suffering
from advanced HCC.
An important difference between our study and previous
studies was the continuous administration of sorafenib,
which may have also contributed to the survival beneﬁt we
observed. In the SHARP trial [12], a survival time of
5.2 months was reported after disease progression. In a
Japanese phase I study of sorafenib [33], despite the
median TTP being only 4.9 months, the median OS was
relatively long (15.6 months). Yau et al. [24] reported that,
even in patients who did not demonstrate any clinical
beneﬁts with sorafenib, OS was substantially better com-
pared with their historical cohort. Wo ¨rns et al. [34]
reported that radiologic disease stabilization (PR ? SD)
was achieved in 50 % of patients after a median of
3.2 months or at least a clinically stable presentation in a
subset of patients with radiologic PD leading to continua-
tion of therapy. These ﬁndings suggest that even the
patients who exhibited no demonstrable clinical beneﬁts
with sorafenib treatment might obtain a survival beneﬁt
from the drug. Therefore, applying radiologic progression
criteria would be likely to lead to the discontinuation of
sorafenib therapy after 3–4 months in these cases, hence
potentially denying these patients the opportunity to con-
tinue to receive clinical beneﬁt and improved OS. We
suggest that the decision to continue sorafenib therapy after
radiologic progression is justiﬁed in patients with contin-
uing clinically stable presentation.
Cell Biochem Biophys (2012) 63:159–169 167
123Besides, sub-analyses were conducted on the basis of
various factors associated with the prognosis of HCC
patients that included age, the largest tumor diameter,
tumor difference, ECOG PS, Child-Pugh class, and HBV
DNA load. Our data show that sorafenib provided beneﬁt
to all the subpopulations analyzed, including those patients
who normally show the worst outcomes. However, in
patients with an ECOG PS of 2, those with the largest
tumor diameter[7 cm, Child-Pugh class B, and high HBV
DNA load, we also analyzed the correlation between
treatment-related toxicities and prognosis. In corroboration
to the previous ﬁndings [35], we found that fatigue, weight
loss, and liver toxicity correlated, to some extent, with poor
DCR, TTP, and OS. In another study [24], fatigue was
observed in 50 % of patients. In the present study, 44 % of
patients exhibited fatigue. We believe that severe fatigue
may be a predictor of poor prognosis to a certain degree.
Liver toxicity is an important issue during sorafenib
treatment and local treatment. CryoRx can induce liver
dysfunction/failure in HCC patients with stage C; however,
addition of CryoRx to sorafenib can further improve the
OS in these HCC patients. The proﬁle, frequency, and
degree of sorafenib-related AEs were comparable to the
previous reports, and cryoRx did not further increase fre-
quency and degree of sorafenib-related AEs. This ﬁnding
suggests that the liver toxicity could be induced by so-
rafenib. Sorafenib can induce liver failure not only in
Child-Pugh B patients but also in Child-Pugh A patients
[36]. However, most sorafenib-induced liver failure, as we
found, occurred in Child-Pugh B patients.
The previous studies [22, 37] reported intratumoral
MVD as a prognostic measure of tumor. A prospective
study [38] found a signiﬁcant positive correlation between
MVD and postoperative recurrence in patients undergoing
resection of HCC B5 cm using CD34 as an endothelial cell
marker. Therefore, we analyzed the correlation between
MVD and response to sorafenib therapy. We found that
mean MVD of patients with CER was signiﬁcantly lower
than that of patients with PD (P\0.001). The results
suggest that MVD affects the clinical response to therapy
in advanced HCC patients. Among patients with low MVD,
we found that those receiving the combination therapy
exhibited a signiﬁcantly longer median TTP and OS than
those receiving sorafenib alone; but among patients with
high MVD, TTP, and OS differed non-signiﬁcantly
between treatment groups. The current data suggest that the
antiangiogenic effects of sorafenib for advanced HCC
patients with a high MVD are mild. Since patients with
complete PVT always have poor liver function (Child-Pugh
class C), extrahepatic spread, and an expected survival time
of less than 3 months, such patients were also excluded.
Regarding the safety and efﬁcacy of sorafenib combined
with local cryoablation technique, further prospective,
randomized, well-designed clinical studies will need to be
taken up in the future.
In conclusion, this clinical study demonstrated that
compared to sorafenib alone, the combined cryoRx and
sorafenib therapy signiﬁcantly improves TTP and OS in
HBV-related BCLC stage C HCC patients with acceptable
tolerance and similar safety proﬁles as previously reported.
High intratumoral MVD was predictive of poor responses
to sorafenib, and these results provide further validation for
targeted therapy approach in advanced HCC patients.
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